|
Secondary malignant neoplasm of bone
|
0.040 |
Biomarker
|
disease |
BEFREE |
Fifty-two patients who received a single 8-Gy RT for painful bone metastases completed the EORTC QOL-C15-PAL questionnaire prior to randomization and at 42-day post RT.
|
29156910 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.040 |
Biomarker
|
disease |
BEFREE |
To determine quality of life (QoL) outcomes after palliation of pain from bone metastases using magnetic resonance-guided high intensity focused ultrasound (MR-guided HIFU), measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL and the QLQ-BM22 questionnaires.
|
29317145 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.040 |
Biomarker
|
disease |
BEFREE |
Patients completed the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) bone metastases module (QLQ-BM22) and EORTC QOL Core-15-Palliative (QLQ-C15-PAL) before treatment and at days 10 and 42 after a single 8 Gy radiation treatment.
|
29156903 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.040 |
Biomarker
|
disease |
BEFREE |
Self-reported QOL was completed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Bone Metastases Module (QLQ-BM22) and the European Organisation for Research and Treatment of Cancer Quality of Life Core 15 Palliative (QLQ-C15-PAL) at the same time points.
|
28196208 |
2017 |
|
Influenza
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moreover, the sequence had a high degree of similarity to the peptidoglycan-associated outer membrane lipoprotein P6 of Haemophilus influenzae and the peptidoglycan-associated lipoprotein PAL of E. coli.
|
8576327 |
1995 |
|
Influenza
|
0.020 |
Biomarker
|
disease |
BEFREE |
Previous studies indicated that Actinobacillus pleuropneumoniae PalA is homologous to a Haemophilus influenzae protective antigen Hi-PAL (P6) protein.
|
28828973 |
2017 |
|
Alopecia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Analysis of the QLQ-C15-PAL and BN20 scales revealed significant deterioration in patients treated with WBRT and SRT in physical function (p < 0.001 and p = 0.007), fatigue (p < 0.001 and p = 0.036), nausea (p = 0.003 and p = 0.002), appetite loss (p < 0.001 and p = 0.025), drowsiness (p < 0.001 and p = 0.011), hair loss (p = 0.019 and p = 0.023) and itchy skin (p = 0.030 and p = 0.018).
|
31418046 |
2020 |
|
Anorexia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Analysis of the QLQ-C15-PAL and BN20 scales revealed significant deterioration in patients treated with WBRT and SRT in physical function (p < 0.001 and p = 0.007), fatigue (p < 0.001 and p = 0.036), nausea (p = 0.003 and p = 0.002), appetite loss (p < 0.001 and p = 0.025), drowsiness (p < 0.001 and p = 0.011), hair loss (p = 0.019 and p = 0.023) and itchy skin (p = 0.030 and p = 0.018).
|
31418046 |
2020 |
|
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
VEGFR-2 expressing stromal blood vessels, also positive for the vascular endothelial marker PAL-E and the basement membrane marker laminin, were more abundant in RA and AS than in controls.
|
11824969 |
2002 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
A lectin with strong cytotoxic effect on human colon cancer HT29 and monkey kidney VERO cells was recently identified from the Australian indigenous mushroom Psathyrella asperospora and named PAL.
|
28168856 |
2017 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We retrospectively compared 33 consecutive cases treated with 18-mm-diameter stents (bridge to surgery [BTS] in 25, palliative therapy [PAL] in 8) with 27 consecutive cases treated with 22-mm-diameter stents (BTS in 21, PAL in 6) for obstructive colorectal cancer between May 2013 and November 2015 in our institution.
|
29258112 |
2017 |
|
Mental Depression
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NEIS, HADS and EORTC QLQ-C15-PAL were assessed at baseline (T0), 1 month later (post-treatment; T1), and at 1 month follow-up (T2).AMT was assessed at T0 and T1.
|
29763431 |
2018 |
|
Depressive disorder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NEIS, HADS and EORTC QLQ-C15-PAL were assessed at baseline (T0), 1 month later (post-treatment; T1), and at 1 month follow-up (T2).AMT was assessed at T0 and T1.
|
29763431 |
2018 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
The PAL project develops a conversational agent with a physical (robot) and virtual (avatar) embodiment to support diabetes self-management of children ubiquitously.
|
29548599 |
2018 |
|
Erythema Chronicum Migrans
|
0.010 |
Biomarker
|
disease |
BEFREE |
The DNA profile of NCH-1 was most similar to those of strain 297 (human cerebrospinal fluid isolate, Connecticut) and strain PAL (human erythema migrans isolate, New York) and most dissimilar from those of strain P/Gau (human erythema migrans isolate, Germany) and strain IPF (Ixodes persulcatus tick isolate, Japan).
|
1551988 |
1992 |
|
Gingivitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
PAL-V achieved by regenerative therapy in infrabony defects is as stable over 5 years as periodontally reduced but gingivally healthy or gingivitis sites.
|
30972774 |
2019 |
|
Glossitis, Benign Migratory
|
0.010 |
Biomarker
|
disease |
BEFREE |
The DNA profile of NCH-1 was most similar to those of strain 297 (human cerebrospinal fluid isolate, Connecticut) and strain PAL (human erythema migrans isolate, New York) and most dissimilar from those of strain P/Gau (human erythema migrans isolate, Germany) and strain IPF (Ixodes persulcatus tick isolate, Japan).
|
1551988 |
1992 |
|
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
(Palliative Care in Heart Failure [PAL-HF]; NCT01589601).
|
28705314 |
2017 |
|
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
(Palliative Care in Heart Failure [PAL-HF]; NCT01589601).
|
28705314 |
2017 |
|
Hemangioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
By contrast, blood vessel endothelium and hemangiomas were strongly positive for PAL-E and CD34 but were mostly negative for CD9 and podoplanin.
|
14559986 |
2003 |
|
Lymphangioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Regular lymphatic endothelium and lymphangiomas were strongly positive for CD9 and podoplanin but were mostly negative for PAL-E and CD34.
|
14559986 |
2003 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MoAb PAL-M1 reacted with all 15 melanoma metastases (MM), with 14 of 19 primary cutaneous melanomas (PCM), 9 of 35 dysplastic nevi (DN), and 2 of 26 NN.
|
3891875 |
1985 |
|
Melanocytic nevus
|
0.010 |
Biomarker
|
disease |
BEFREE |
MoAb PAL-M1 reacted with all 15 melanoma metastases (MM), with 14 of 19 primary cutaneous melanomas (PCM), 9 of 35 dysplastic nevi (DN), and 2 of 26 NN.
|
3891875 |
1985 |
|
Kaposi Sarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Using immunohistochemistry, expression of CD9 was studied in 17 samples of head and neck mucosa and skin (laryngeal mucosa: n = 2, oral: n = 6, and epidermis: n = 9) and a variety of vascular tumors (lymphangiomas: n = 9, juvenile nasopharyngeal angiofibromas: n = 4, hemangiomas: n = 7, angiosarcomas: n = 5, and Kaposi's sarcomas: n = 7) and compared with the expression of CD34 and PAL-E (blood vessel markers) and the lymphatic marker podoplanin.
|
14559986 |
2003 |
|
Systemic Scleroderma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Daily physical activities (243 ± 145 min per day vs 397 ± 142 min, respectively; P = 0.005) and PAL were significantly reduced in SSc compared with controls (1.5 ± 0.4 vs 2 ± 0.7, respectively; P = 0.019).
|
25832135 |
2017 |